XRTX vs DBVT vs PRGO vs HALO vs ARWR

For growth investors, Arrowhead Pharmaceuticals, Inc.

(ARWR) is the stronger pick with 232. 6% revenue growth year-over-year, versus -2. 8% for Perrigo Company plc (PRGO). Halozyme Therapeutics, Inc. (HALO) offers the better valuation at 25. 5x trailing P/E (8. 1x forward), making it the more compelling value choice. Analysts rate DBV Technologies S. A. (DBVT) a "Buy" — based on 15 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On forward P/E, Perrigo Company plc is actually cheaper at 5.

6x — notably different from the trailing picture, reflecting expected earnings growth.

Over the past 5 years, Halozyme Therapeutics, Inc.

(HALO) delivered a total return of +37. 0%, compared to -96. 3% for XORTX Therapeutics Inc. (XRTX). Over 10 years, the gap is even starker: ARWR returned +1253% versus XRTX's -96. 5%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Halozyme Therapeutics, Inc.

(HALO) is the lower-risk stock at 0. 56β versus Arrowhead Pharmaceuticals, Inc. 's 1. 81β — meaning ARWR is approximately 225% more volatile than HALO relative to the S&P 500. On balance sheet safety, XORTX Therapeutics Inc. (XRTX) carries a lower debt/equity ratio of 2% versus 135% for Perrigo Company plc — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Arrowhead Pharmaceuticals, Inc.

(ARWR) is pulling ahead at 232. 6% versus -2. 8% for Perrigo Company plc (PRGO). On earnings-per-share growth, the picture is similar: Arrowhead Pharmaceuticals, Inc. grew EPS 99. 8% year-over-year, compared to -723. 2% for Perrigo Company plc. Over a 3-year CAGR, ARWR leads at 50. 5% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Halozyme Therapeutics, Inc.

(HALO) is the more profitable company, earning 22. 7% net margin versus -33. 5% for Perrigo Company plc — meaning it keeps 22. 7% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: HALO leads at 58. 4% versus 0. 0% for DBVT. At the gross margin level — before operating expenses — ARWR leads at 97. 1%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, Perrigo Company plc (PRGO) trades at 5.

6x forward P/E versus 8. 1x for Halozyme Therapeutics, Inc. — 2. 5x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for DBVT: 131. 8% to $46. 33.

In this comparison, PRGO (9.

8% yield) pays a dividend. XRTX, DBVT, HALO, ARWR do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Halozyme Therapeutics, Inc.

(HALO) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 56), +570. 7% 10Y return). Both have compounded well over 10 years (HALO: +570. 7%, DBVT: -87. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: XRTX is a small-cap quality compounder stock; DBVT is a mega-cap quality compounder stock; PRGO is a small-cap income-oriented stock; HALO is a small-cap high-growth stock; ARWR is a mid-cap high-growth stock. PRGO pays a dividend while XRTX, DBVT, HALO, ARWR do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.